US7574681034 - ADR - After market: 0.2231 -0.01 (-2.75%)
NASDAQ:RDHL (2/3/2023, 7:04:38 PM)+0 (+1.5%)
|GICS Sector||Health Care|
|Earnings (Last)||11-07 2022-11-07/bmo||Earnings (Next)||03-15 2023-03-15/amc|
|Ins Owners||N/A||Inst Owners||3.12%|
Find more stocks on Nasdaq
Find more stocks on the USA
Find competitors from the same sector on the USA
Find competitors from the same industry on the USA
Find stocks with similar TA and Setup ratings on the USA
Find stocks with similar Fundamental rating on the USA
Find the competitors with the best technical ratings on the USA
Find the competitors with the best technical and setup ratings on the USA
Find the competitors with the best fundamentals on the USA
Find the competitors with the best valuation on the USA
Find the competitors with the best dividend on the USA
Find the competitors with the best analyst ratings on the USA
RedHill Biopharma Ltd. develops medicines for gastrointestinal and infectious diseases. The firm is focused on the commercialization in the United States (U.S.) of the GI-related products, Movantik (naloxegol),Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). A part form Company's pipeline consists of six therapeutic candidates RHB-204 dedicated to Nontuberculous mycobacterial (NTM) treatment, RHB-104 dedicated to Crohn's disease, RHB-102 antiemetic drug ondansetron, in development for multiple gastrointestinal indications, RHB-106 an oral capsule formulation for bowel preparation, Opaganib an inhibitor, administered orally, with anticancer, anti-inflammatory and anti-viral activities and RHB-107 inhibitor of serine proteases targeting multiple indications, including COVID-19, cancer, inflammatory lung diseases and gastrointestinal diseases.
REDHILL BIOPHARMA LTD-SP ADR
21 Ha'arba'a St.
TEL AVIV-YAFO 64739
CEO: Dror Ben-Asher
Let's have a look at the most active stocks in today's session.
Let's have a look at what is happening on the US markets on Friday. Below you can find the gap up and gap down stocks in today's session.
GeneDx (WGS) stock is taking a beating on Friday after the company revealed a $150 million proposed public stock offering.
ContraFect (CFRX) stock is falling on Friday after the company provided an update on its potential delisting from the Nasdaq Capital Market.
The US market session of Friday has yet to be opened, let's have a look at the top gainers and losers in the pre-market session today.
Akanda (AKAN) stock is on the rise Friday as the company's shares continue a rally that started yesterday following an FDA update.
Here you can normally see the latest stock twits on RDHL, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.